Schneider et al developed a simple score based on flow cytometry to evaluate a patient with acute myeloid leukemia (AML). The markers studied reflect cellular maturity. The authors are from multiple hospitals in Germany.
Patient selection: AML
Analysis: flow cytometry
Parameters:
(1) percent expression of CD34
(2) percent expression of CD117
(3) percent expression of TdT
(4) age of the patient in years
|
Parameter |
Finding |
Points |
|
CD34 |
< 20% |
0 |
|
|
20 to 49% |
1 |
|
|
>= 50% |
2 |
|
CD117 |
< 20% |
0 |
|
|
20 to 49% |
0.5 |
|
|
>= 50% |
1 |
|
TdT |
< 10% |
0 |
|
|
10 to 49% |
1 |
|
|
>= 50% |
2 |
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the more immature the blasts.
• A patient < 60 years of age tended to have better outcomes than a patient >= 60 years.
|
Total Score |
Designation |
Mean Overall Survival |
|
0 to 1 |
mature (AML-ma) |
64 months |
|
1.5 to 5 |
immature (AML-im) |
33 months |
Specialty: Hematology Oncology
